Elevating Synaptic Biomarkers in Epilepsy: Unlocking the Potential of CSF & Plasma SV2A for Structural Disease Diagnosis

• Explore emerging evidence that SV2A, a marker of synaptic density and the target of levetiracetam, is elevated in CSF and plasma in patients with structural epilepsy, highlighting its potential as a novel fluid biomarker
• Learn how CSF and plasma SV2A measurements correlate with lesion status, temporal lobe pathology, seizure timing, and established markers of neuronal injury, providing new insights into disease activity and biomarker interpretation
• Understand the analytical validation of SV2A detection using ELISA and Western blot, the specificity of SV2A compared with other SV2 isoforms, and the opportunities and challenges of translating synaptic biomarkers into clinical practice for epilepsy diagnosis and monitoring

Speakers:

Jens Mikkelsen

Professor, University of Copenhagen

Institute of Neuroscience